John leads the Value Evidence and Outcomes (VEO) organization within GlaxoSmithKline’s R&D division. The VEO organization is accountable for the evidence generation strategy and implementation as well as providing strategic input into the progression of assets. The VEO organization leads the strategy behind all Real-World Evidence within GSK.
John moved to GSK in June of 2014 to lead the CV,Met,Ren,NS and Rare Disease VEO teams and in November 2015 was appointed as Head for the entire VEO organization. John holds a Doctorate of Pharmacy degree from Idaho State University as well as a Residency Certificate from the University of Nebraska Medical Center. He has published multiple articles across various TAs. Previously John worked for 16 years at Bristol-Myers Squibb with positions across both US and Global Medical eventually leading the US HEOR function.